Simulations Plus And The University Of Southern California Secure NIH Grant To Develop New AI Drug Discovery Offerings
Portfolio Pulse from Benzinga Newsdesk
Simulations Plus, Inc. (NASDAQ:SLP) has secured a research grant from the NIH in partnership with USC to develop AI-driven drug discovery solutions. This initiative aims to enhance ligand-based virtual screening for pharmaceutical companies.
October 08, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Simulations Plus has secured a NIH grant in partnership with USC to develop AI-driven drug discovery solutions, enhancing their offerings in ligand-based virtual screening.
The NIH grant and partnership with USC will likely enhance Simulations Plus's product offerings and market position in the pharmaceutical industry. The focus on AI-driven drug discovery solutions aligns with current industry trends, potentially leading to increased demand for their services.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90